European Archives - Page 664 of 1348 - European Medical Journal

Revealing the true value of medical affairs

Why is the purpose and value of medical affairs sometimes poorly understood by the wider pharma organisation, and what can be done?

Meet GOLD's new catalyst – GSK's John Wahba

Helena and Isabel share an interview with GOLD’s new catalyst John Wahba, Medical Head of the Global Digital Hub, GS

Davidek Herron on the future of pharma

In his second column, Davidek Herron, Global Head of Digital, Roche, considers this year’s successes and challenges and looks ahead to 2023.

Çetin Erol

Interview: Çetin Erol

We are honoured to share our EMJ Cardiology 2022 in review interview with Çetin Erol, Cardiologist at İbn-i Sina Hospital, Faculty of…

Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Chaired by Prof. Andrea Necchi, this symposium presented by Prof. Rouprêt and Prof. Retz explores the treatment landscape for muscle-invasive urothelial carcinoma, as well as their perspectives on future treatment landscape.

Interview: Antonio Rossi

We are honoured to share our EMJ Respiratory interview with Antonio Rossi, Senior Medical Director, Oncology Center of Excellence…

EMJ Oncology 10 [Supplement 12] 2022

This article covers a symposium that took place on 10th September 2022 as part of the European Society for Medical Oncology (ESMO) annual congress held in Paris, France, from 9th–13th September 2022.

Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine

Cholangiocarcinoma (CCA) is a cancer of the bile duct with poor prognosis and increasing incidence. Filippo de Braud gave an overview of CCA and its classification and highlighted key unmet needs in both diagnosis and treatment. Juan Valle explained that intrahepatic CCA (iCCA) accounts for 11% of the entire cancer of unknown primary (CUP) population, as well as 33% of patients with liver-inclusive disease.

Aetiology and Outcomes of Thrombocytopenia in Pregnancy: A Cross-Sectional Study in a University Hospital, India

Thrombocytopenia (TCP) is the second most common haematological finding in pregnancy next to anaemia. It carries a risk for both the mother and the fetus, associated with substantial maternal or neonatal morbidity and mortality. However, a specific therapy, if instituted promptly, improves the outcome for affected patients and their offspring. In patients in India, TCP during pregnancy is an underexplored condition.

IME Rheumatology Webinar | Key Insights from ACR 2022: An Interdisciplinary Expert Roundtable Discussion

Join us for a roundtable discussion to gain a deeper understanding of emerging data from ACR 2022 and real-world evidence with biosimilars…